Genomic Analysis and 3-Year Efficacy and Safety Update of COMBI-d<br />A phase 3 study of dabrafenib + trametinib vs dabrafenib monotherapy in patients with unresectable or
metastatic BRAF V600E/K–mutant cutaneous melanoma
Presented By Keith Flaherty at 2016 ASCO Annual Meeting
36% LDH elevada
67% M1c
73% ECOG 0-1
85% V600E, 15% V600K
